Robatumumab
Robatumumab
Robatumumab (pronounced roh-ba-TOO-moo-mab) is a monoclonal antibody designed for the treatment of cancer. It is a type of biological therapy that targets specific proteins on cancer cells to inhibit their growth and spread.
Etymology
The name "Robatumumab" is derived from the International Nonproprietary Names (INN) system for pharmaceutical substances. The "-mab" suffix indicates that it is a monoclonal antibody, while the "tumu" infix suggests its use in tumor-related conditions. The prefix "Roba-" does not have a specific meaning and is used for unique identification.
Mechanism of Action
Robatumumab works by binding to the epidermal growth factor receptor (EGFR), a protein found on the surface of some cancer cells. By blocking EGFR, Robatumumab can inhibit the growth and division of cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Epidermal growth factor receptor (EGFR): A protein found on the surface of some cells to which epidermal growth factor binds, causing the cells to divide.
- Biological therapy: Treatment to stimulate or restore the ability of the immune system to fight infection and disease.
See Also
External links
- Medical encyclopedia article on Robatumumab
- Wikipedia's article - Robatumumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski